troleandomycin has been researched along with omeprazole in 9 studies
Studies (troleandomycin) | Trials (troleandomycin) | Recent Studies (post-2010) (troleandomycin) | Studies (omeprazole) | Trials (omeprazole) | Recent Studies (post-2010) (omeprazole) |
---|---|---|---|---|---|
569 | 26 | 23 | 9,085 | 2,737 | 1,487 |
Protein | Taxonomy | troleandomycin (IC50) | omeprazole (IC50) |
---|---|---|---|
Mcl-1 | Homo sapiens (human) | 3.1448 | |
cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.28 | |
Potassium-transporting ATPase alpha chain 1 | Homo sapiens (human) | 1.45 | |
Cytochrome P450 2C19 | Homo sapiens (human) | 2.315 | |
Potassium-transporting ATPase subunit beta | Homo sapiens (human) | 1.45 | |
WD repeat-containing protein 5 | Homo sapiens (human) | 1.7 | |
Glutathione S-transferase omega-1 | Homo sapiens (human) | 4.6 | |
Histone-lysine N-methyltransferase 2A | Homo sapiens (human) | 1.7 | |
Muscarinic acetylcholine receptor | Cavia porcellus (domestic guinea pig) | 3.8 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (22.22) | 18.2507 |
2000's | 4 (44.44) | 29.6817 |
2010's | 3 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Pratim Roy, P; Roy, K | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Ishizaki, T; Zhao, XJ | 1 |
Kitamura, S; Konishi, T; Nishikawa, H; Taguchi, K | 1 |
He, N; Huang, SL; Shu, Y; Wang, LS; Wang, W; Xiao, WM; Xu, ZH; Zhou, HH | 1 |
He, N; Huang, SL; Liu, J; Tan, ZR; Zhou, HH; Zhu, B; Zhu, RH | 1 |
Marks, B; Raucy, J; Trubetskoy, O; Yueh, MF; Zielinski, T | 1 |
1 trial(s) available for troleandomycin and omeprazole
Article | Year |
---|---|
Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; DNA; Genotype; Half-Life; Humans; Male; Mixed Function Oxygenases; Omeprazole; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Polymerase Chain Reaction; Troleandomycin | 2003 |
8 other study(ies) available for troleandomycin and omeprazole
Article | Year |
---|---|
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Topics: Anti-Infective Agents; Antimalarials; Chromatography; Cytochrome P-450 Enzyme System; Doxycycline; Drug Interactions; Erythromycin; Humans; Hydroxylation; Ketoconazole; Microsomes, Liver; Nifedipine; Omeprazole; Primaquine; Quinine; Tetracycline; Troleandomycin | 1997 |
Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aryl Hydrocarbon Hydroxylases; Benzoflavones; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drugs, Chinese Herbal; Enzyme Inhibitors; Glycyrrhiza; Humans; Isoenzymes; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Paeonia; Phenylpropionates; Quinidine; Recombinant Proteins; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Sulfaphenazole; Troleandomycin | 1999 |
5-hydroxylation of omeprazole by human liver microsomal fractions from Chinese populations related to CYP2C19 gene dose and individual ethnicity.
Topics: Adult; Antibodies, Monoclonal; Aryl Hydrocarbon Hydroxylases; China; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ethnicity; Gene Dosage; Genotype; Humans; Hydroxylation; Mephenytoin; Microsomes, Liver; Mixed Function Oxygenases; Omeprazole; Substrate Specificity; Troleandomycin | 2000 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dimethyl Sulfoxide; Enhancer Elements, Genetic; Enzyme Induction; Genes, Reporter; Genes, Synthetic; Humans; Ketoconazole; Liver Neoplasms; Lovastatin; Luciferases; Mifepristone; Neoplasm Proteins; Nifedipine; Omeprazole; Paclitaxel; Phenytoin; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Fusion Proteins; Rifampin; Thiazolidinediones; Transcription, Genetic; Troglitazone; Troleandomycin | 2005 |